Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Development and validation of a weighted cytokine scoring system for immune status Assessment Following CD19 CAR-T Therapy

Dongchu Wang, Fei Wang, Hui Wang Nov 03, 2025 pp. 5141-5141 10.1182/blood-2025-5141

Abstract Background and Aims This study developed and validated a novel immune status evaluation system utilizing multiplex cytokine profili...

Deep learning-based histopathological subtyping of peripheral T-cell lymphoma (PTCL) on H&E-stained whole slide images

Sarah Bernhardt, Leonie Oevel, Hilka Rauert-Wunderlich et al. Nov 03, 2025 pp. 1784-1784 10.1182/blood-2025-1784

Abstract Introduction Peripheral T-cell lymphomas (PTCL) are rare and highly heterogenous malignancies. The diagnosis ca...

Development of a novel LRP1 antibody that identifies upregulation of membrane LRP1 on activated and chimeric antigen receptor T cells

Rolando Vedia, Dan Li, Lisa St. John et al. Nov 03, 2025 pp. 7637-7637 10.1182/blood-2025-7637

Abstract Low-density lipoprotein receptor-related protein 1 (LRP1) is a member of the LDL receptor family which plays a variety of different...

Space associated stem cell hallmarks of aging (SASHA) in astronauts

Jessica Pham, Shuvro Nandi, Larissa Balaian et al. Nov 03, 2025 pp. 1383-1383 10.1182/blood-2025-1383

Abstract Previous reports revealed immune dysfunction, chromosomal abnormalities, cytokine deregulation, and telomere length dynamics follow...

Ibrutinib in the treatment of allogeneic stem cell transplant-related pure red cell aplasia: A single center experience

Roberta Azbell, Lexus Frazier, Justin Tossey et al. Nov 03, 2025 pp. 2443-2443 10.1182/blood-2025-2443

Abstract Background: Allogeneic stem cell transplantation (alloSCT) is a potentially curative treatment for several hematologic disorders, a...

Predicting genetic alterations in Acute Myeloid Leukemia through AI-based analysis of bone marrow morphology

David Bermejo-Peláez, Ana Mendoza Martínez, Miguel Gómez Álvarez et al. Nov 03, 2025 pp. 6124-6124 10.1182/blood-2025-6124

Abstract Acute myeloid leukemia (AML) is characterized by significant genetic heterogeneity, with diverse cytogenetic and molecular alterati...

Central nervous system relapse is uncommon after chimeric antigen receptor T-cell therapy for relapsed/refractory large B-cell lymphoma

Gloria Iacoboni, Emmanuel Bachy, Victor Navarro et al. Nov 03, 2025 pp. 5497-5497 10.1182/blood-2025-5497

Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has significantly improved the prognosis of patien...

Invariant patterns of global mutational signatures allow new fundamental insights in etiopathogenesis of bone marrow failure including aplastic anemia and myelodysplasia

Felipe de Almeida Sartori, Arda Durmaz, Carlos Bravo-Perez et al. Nov 03, 2025 pp. 4985-4985 10.1182/blood-2025-4985

Abstract WGS data enables the definition of individual somatic mutational signatures (MS) through mathematical algorithms by identifying dis...

Iron deficiency at neonatal intensive care unit discharge in very preterm infants

Victoria Hamilton, Hudson Barr, Nathan Mckenzie et al. Nov 03, 2025 pp. 2910-2910 10.1182/blood-2025-2910

Abstract Introduction: ID is the most common micronutrient deficiency worldwide. Preterm infants are especially vulnerable to ID due to low...

Redefining eIF4E's function in Acute Myeloid Leukemia: Implications for engraftment and survival

Leandro Martinez, Biljana Kraljacic, Kata Alilovic et al. Nov 03, 2025 pp. 3248-3248 10.1182/blood-2025-3248

Abstract The crosstalk between acute myeloid leukemia (AML) cells and the bone marrow niche is crucial for disease progression. Modeling the...

High morbidity in adults with non-transfusion-dependent thalassemia referred to u.S. specialty centers

Aaron Cheng, Scott Peslak, Sujit Sheth et al. Nov 03, 2025 pp. 1141-1141 10.1182/blood-2025-1141

Abstract Introduction Non-transfusion-dependent thalassemia (NTDT) is a clinically significant form of thalassemia associated with progressi...

Revumenib in combination with intensive induction and consolidation for newly diagnosed patients with NPM1-mutated or KMT2A-rearranged Acute Myeloid Leukemia: Preliminary results from the Phase 1b etctn 10596 study

Alice Mims, Lai Wei, Eric McLaughlin et al. Nov 03, 2025 pp. 5206-5206 10.1182/blood-2025-5206

Abstract Introduction: Revumenib is a first-in-class FDA-approved menin inhibitor that has shown efficacy in patients (pts) with relapsed/re...

The need for a subsequent HCT is a late & continuous risk and with significant impact in overall survival in haemoaglobinopathies: Real-world data from 2000–2022. an analysis of the european society for blood and marrow transplantation (EBMT) hemoglobinopathy working party.

Josu de la Fuente, Donatella Baronciani, Mathilde Fekom et al. Nov 03, 2025 pp. 178-178 10.1182/blood-2025-178

Abstract INTRODUCTION: Allogeneic hematopoietic cell transplantation (HCT) is the best established curative option for sickle cell disease (...

A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized study

Agnieszka Wierzbowska, Anna Czyz, Agnieszka Pluta et al. Nov 03, 2025 pp. 1737-1737 10.1182/blood-2025-1737

Abstract BACKGROUND: Measurable residual disease (MRD) is increasingly recognized as a critical prognostic factor in AML for guiding therape...

Echocardiographic findings over time in sickle cell disease patients: A single-center study

Nehaa Dambala, Kok Hoe Chan, Modupe Idowu Nov 03, 2025 pp. 6504-6504 10.1182/blood-2025-6504

Abstract Background Patients with sickle cell disease (SCD) are at risk for cardiovascular sequelae, most notably pulmonary hypertension and...

Signaling role of viral protein motif and its application in CAR T cell therapy

Wooram Jung, Kunho Chung, Jude Franklin et al. Nov 03, 2025 pp. 5892-5892 10.1182/blood-2025-5892

Abstract CD19-targeted Chimeric Antigen Receptor (CAR) T cell therapy is a leading treatment for B-cell malignancies, achieving complete rem...

Treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib following a switch from ruxolitinib: The my-PAC study

Douglas Tremblay, Abiola Oladapo, Michael Marrone et al. Nov 03, 2025 pp. 5577-5577 10.1182/blood-2025-5577

Abstract Background: Ruxolitinib (RUX) is a JAK1/2 inhibitor known to induce myelosuppression and is often used at suboptimal doses in patie...

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

Monzr M. Al Malki, Susanta Hui, Dongyun Yang et al. Nov 03, 2025 pp. 376-376 10.1182/blood-2025-376

Abstract Older adults with R/R acute leukemia or MDS have dismal treatment outcomes. TMLI is a targeted radiotherapy platform that enables r...

Dosing variability of tyrosine kinase inhibitors in chronic myeloid leukemia

Joshua Knapp, Kendall Diebold, Devan Parker et al. Nov 03, 2025 pp. 6398-6398 10.1182/blood-2025-6398

Abstract Introduction Tyrosine kinase inhibitors (TKIs) have been the standard therapy for chronic myeloid leukemia (CML) since 2001. The cu...

Prescribing patterns in MDS/MPN syndromes

Kirti Arora, Jahanvi Grover, Kelsey Pandrangi et al. Nov 03, 2025 pp. 7375-7375 10.1182/blood-2025-7375

Abstract Introduction: Myelodysplastic Syndrome (MDS)-Myeloproliferative Neoplasms (MPN) overlap syndromes, such as Chro...

Single-cell transcriptomic and clonotypic characterization of Waldenström macroglobulinemia reveals intra-patient monoclonal diversity with distinct differentiation states

Minghao Dang, Sherif Seif, Maria Acevedo-Calado et al. Nov 03, 2025 pp. 460-460 10.1182/blood-2025-460

Abstract Background: Waldenström macroglobulinemia (WM) is a rare, indolent B-cell lymphoma characterized by bone marrow (BM) infiltration o...

BuCy combined with cladribine and medium-dose cytarabine as an intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation in T-ALL/lbl patients

Tingting Cheng, Yan Chen, Fangping Chen et al. Nov 03, 2025 pp. 2421-2421 10.1182/blood-2025-2421

Abstract Background: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been regarded as the most effective curative therapy...

Phase I study of the histone deacetylase inhibitor panobinostat in sickle cell disease

Abdullah Kutlar, Chithra Palani, Leigh Wells et al. Nov 03, 2025 pp. 613-613 10.1182/blood-2025-613

Abstract Introduction: Reactivation of HbF in adult life is a proven effective therapy for β-hemoglobinopathies. Hydroxyurea (HU) is the onl...

Beyond mutations: RNA editing deaminase activation as a dynamic marker to track stem cell fitness and MPN progression

Inge Van Der Werf, Jessica Pham, Neha Katragadda et al. Nov 03, 2025 pp. 5543-5543 10.1182/blood-2025-5543

Abstract Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell–derived disorders that can progress to acute myeloid leukemi...

Proliferation of mature plasmacytoid dendritic cells in RUNX1-mutated Acute Myeloid Leukemia

Marina Serra Carrera, Sara Garrido Paniagua, Carlos Palacio et al. Nov 03, 2025 pp. 7004-7004 10.1182/blood-2025-7004

Abstract Introduction: Clonal expansion of mature plasmacytoid dendritic cells (pDCs), traditionally linked to chronic m...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page